Full Press Release Details
WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory skin diseases, today announced that Bradley Burnam, Chief Executive Officer, and Stephen M. Hahn, M.D., Executive Clinical and Regulatory Lead, will join in a U.S. Bancorp | BTIG virtual fireside chat as follows: Date: Wednesday, October 28, 2026 Time: 10:00 AM ET The fireside chat, "Building a Program for Patient A